Moreover in a different human colon cancer cell line (HT29) and derived mouse xenografts, EGCG lessened VEGF expression and its promoter activity, while decreasing the tumour growth and microvessel density in mice (treated daily intraperitoneally with 1.5 mg EGCG), and modulating cell proliferation and apoptosis in HT29 cells [138]. This evidence concerns the gene VEGFA and colonic neoplasm.